DNA crosslinks, DNA damage and repair in peripheral blood lymphocytes of non-small cell lung cancer patients treated with platinum derivatives

Oncology Reports

Volumn 31, Issue 1, 2014, Pages 391-396

  Fikrova, Petra ^a,b   Stetina, Rudolf ^b,c   Hrnciarik, Michal ^b   Hrnciarikova, Dana ^b   Hronek, Miloslav ^a,b   Zadak, Zdenek ^b  

^a Charles University in Prague Faculty of Pharmacy   (Czech Republic)

^b UNIVERSITY HOSPITAL HRADEC KRALOVE   (Czech Republic)

^c UNIVERSITY OF DEFENCE   (Czech Republic)

Author keywords

Comet assay; DNA damage; DNA repair; Non small cell lung cancer

Indexed keywords

CARBOPLATIN; CELL DNA; CISPLATIN; PLATINUM DERIVATIVE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER PATIENT; CANCER STAGING; CANCER SURVIVOR; CLINICAL ARTICLE; CONTROLLED STUDY; DNA ADDUCT; DNA CROSS LINKING; DNA REPAIR; EXCISION REPAIR; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; SINGLE STRANDED DNA BREAK;

AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; COMET ASSAY; DNA ADDUCTS; DNA BREAKS, SINGLE-STRANDED; DNA REPAIR; FEMALE; HELA CELLS; HUMANS; LUNG NEOPLASMS; LYMPHOCYTES; MALE; MIDDLE AGED;

EID: 84891919147     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2013.2805     Document Type: Article

References (35)

1. Crohns M, Liippo K, Erhola M, Kankaanranta H, Moilanen E, Alho H and Kellokumpu-Lehtinen P: Concurrent decline of several antioxidants and markers of oxidative stress during combination chemotherapy for small cell lung cancer. Clin Biochem 12: 1236-1245, 2009.
2. Gurubhagavatula S, Liu G, Park S, Zhou W, Su L, Wain JC, Lynch TJ, Neuberg DS, David C and Christiani DC: XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy. J Clin Oncol 22: 2594-2601, 2004.
3. Almeida GM, Duarte TL, Steward WP and Jones GD: Detection of oxaliplatin-induced DNA crosslinks in vitro and in cancer patients using the alkaline comet assay. DNA Repair 5: 219-225, 2005.
4. Rosenberg B: Fundamental studies with cisplatin. Cancer 55: 2303-2316, 1985.
5. Lebwohl D and Canetta R: Clinical development of platinum complexes in cancer therapy: an historical perspective and an update. Eur J Cancer 34: 1522-1534, 1998.
6. Dronkert ML and Kannar R: Repair of DNA interstrand cross-links. Mutat Res 486: 217-247, 2001.
7. Unger FT, Klasen HA, Tchartchian G, de Wilde RL and Witte I: DNA damage induced by cis- and carboplatin as indicator for in vitro sensitivity of ovarian carcinoma cells. BMC Cancer 9: 359, 2009.
8. Rabik CA and Dolan ME: Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev 33: 9-23, 2007.
9. McKenna DJ, McKeown SR and McKelvey-Martin VJ: Potential use of the comet assay in the clinical management of cancer. Mutagenesis 23: 183-190, 2008.
10. Faust F, Kassie F, Knasmuller S, Boedecker RH, Mann M and Mersch-Sundermann V: The use of the alkaline comet assay with lymphocytes in human biomonitoring studies. Mutat Res 566: 209-229, 2004.
11. Collins AR and Ferguson LR: DNA repair as a biomarker. Mutat Res 736: 2-4, 2012.
12. Singh NP, McCoy MT, Tice RR and Schneider EL: A simple technique for the quantitation of low levels of DNA damage in individual cells. Exp Cell Res 175: 184-191, 1988.
13. Collins AR: The comet assay for DNA damage and repair: principles, applications, and limitations. Mol Biotechnol 26: 249-261, 2004.
14. Boyum A: Separation of white blood cells. Nature 204: 793-794, 1964.
15. Collins AR, Dobson VL, Dusinská M, Kennedy G and Stětina R: The comet assay: what can it really tell us? Mutat Res 375: 183-193, 1997.
16. Fikrova P, Stetina R, Hrnciarik M, Rehacek V, Jost P, Hronek M and Zadak Z: Detection of DNA crosslinks in peripheral lymphocytes isolated from patients treated with platinum derivates using modified comet assay. Neoplasma 60: 413-418, 2013.
17. Collins AR, Dušinská M, Horváthová E, Munro E, Savio M and Stětina R: Inter-individual differences in repair of DNA base oxidation, measured in vitro with the comet assay. Mutagenesis 16: 297-301, 2001.
18. Gaivão I, Piasek A, Brevik A, Shaposhnikov S and Collins AR: Comet assay based methods for measuring DNA repair in vitro; estimates of inter- and intraindividual variation. Cell Biol Toxicol 25: 45-52, 2009.
19. Langie SA, Knaapen AM, Brauers KJJ, van Berlo D, van Schooten FJ and Godschalk RWL: Development and validation of a modified comet assay to phenotypically assess nucleotide excision repair. Mutagenesis 21: 153-158, 2006.
20. Azqueta A, Shaposhnikov S and Collins AR: DNA repair measured by the comet assay. In: DNA Repair. Kruman I (ed). InTech, Croatia, 2011. doi: 10.5772/22504, 2011. Available from: http://www.intechopen.com/books/dna-repair/ dna-repair-measured-by-the-comet-assay.
21. Palyvoda O, Polanska J, Wygoda A and Rzeszowska-Wolny J: DNA damage and repair in lymphocytes of normal individuals and cancer patients: studies by the comet assay and micronucleus tests. Acta Biochim Pol 50: 181-190, 2003.
22. Smith TR, Miller MS, Lohman KK, Case LD and Hu JJ: DNA damage and breast cancer risk. Carcinogenesis 24: 883-889, 2003.
23. Rajeswari N, Ahuja YR, Malini U, Chandrashekar S, Balakrishna N, Rao KV and Khar A: Risk assessment in first degree female relatives of breast cancer patients using the alkaline comet assay. Carcinogenesis 21: 557-561, 2000.
24. Sanchez C, Clementi M, Benitez D, Contreras H, Huidobro C and Castellon E: Effect of GnRH analogs on the expression of TrkA and p75 neurotrophin receptors in primary cell cultures from human prostate adenocarcinoma. Prostate 65: 195-202, 2005.
25. Lin X, Wood CG, Shao L, Huang M, Yang H, Dinney CP and Wu X: Risk assessment of renal cell carcinoma using alkaline comet assay. Cancer 110: 282-288, 2007.
26. Schabath MB, Grossman HB, Delclos GL, Hernandez LM, Day RS, Davis BR, Lerner SP, Spitz MR and Wu X: Dietary carotenoids and genetic instability modify bladder cancer risk. J Nutr 134: 3362-3369, 2004.
27. Lou J, He J, Zheng W, Jin L, Chen Z, Chen S, Lin Y and Xu S: Investigating the genetic instability in the peripheral lymphocytes of 36 untreated lung cancer patients with comet assay and micronucleus assay. Mutat Res 617: 104-110, 2007.
28. Tudek B: Base excision repair modulation as a risk factor for human cancers. Mol Aspects Med 28: 258-275, 2007.
29. Paz-Elizur T, Krupsky M, Elinger D, Schechtman E and Livneh Z: Repair of the oxidative DNA damage 8-oxoguanine as a biomarker for lung cancer risk. Cancer Biomark 1: 201-205, 2005.
30. Sánchez-Suárez P, Ostrosky-Wegman P, Gallegos- Hernández F, Peñarroja-Flores R, Toledo-García J, Bravo JL, Del Castillo ER and Benítez-Bribiesca L: DNA damage in peripheral blood lymphocytes in patients during combined chemotherapy for breast cancer. Mutat Res 640: 8-15, 2008.
31. Kopjar N, Garaj-Vrhovac V and Milas I: Assessment of chemotherapy-induced DNA damage in peripheral blood leukocytes of cancer patients using the alkaline comet assay. Teratog Carcinog Mutagen 22: 13-30, 2002.
32. 6-alkylguanine alkyltransferase and poly(ADP-ribose) polymerase-1. Clin Cancer Res 11: 3402-3409, 2005.
33. Wynne P, Newton C, Ledermann JA, Olaitan A, Mould TA and Hartley JA: Enhanced repair of DNA interstrand crosslinking in ovarian cancer cells from patients following treatment with platinum-based chemotherapy. Br J Cancer 97: 927-933, 2007.
34. Li XQ, Li J, Shi SB, Chen P, Yu LC and Bao QL: Expression of MRP1, BCRP, LRP and ERCC1 as prognostic factors in non-small cell lung cancer patients receiving postoperative cisplatin-based chemotherapy. Int J Biol Markers 24: 230-237, 2009.
35. Rosell R, Lord RV, Taron M and Reguart N: DNA repair and cisplatin resistance in non-small-cell lung cancer. Lung Cancer 38: 217-227, 2002.